Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

Calvin J. Cohen, Jean Michel Molina, Isabel Cassetti, Ploenchan Chetchotisakd, Adriano Lazzarin, Chloe Orkin, Frank Rhame, Hans Jürgen Stellbrink, Taisheng Li, Herta Crauwels, Laurence Rimsky, Simon Vanveggel, Peter Williams, Katia Boven

Research output: Contribution to journalArticle

Abstract

Background: In the week 48 primary analysis of ECHO and THRIVE, rilpivirine demonstrated noninferior efficacy and more favourable tolerability versus efavirenz in treatment-naive, HIV-1-infected adults. Pooled 96-week results are presented. Methods: Patients (N1/41368) received rilpivirine 25mg once-daily (q.d.) or efavirenz 600mg q.d., with two background nucleoside/nucleotide reverse transcriptase inhibitors, in two randomized, double-blind, double-dummy Phase III trials. Results: At week 96, response rate (% confirmed viral load

Original languageEnglish
Pages (from-to)939-950
Number of pages12
JournalAIDS (London, England)
Volume27
Issue number6
DOIs
Publication statusPublished - Mar 27 2013

Keywords

  • Efavirenz
  • HIV-1
  • Rilpivirine
  • Treatment naive

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials'. Together they form a unique fingerprint.

  • Cite this

    Cohen, C. J., Molina, J. M., Cassetti, I., Chetchotisakd, P., Lazzarin, A., Orkin, C., Rhame, F., Stellbrink, H. J., Li, T., Crauwels, H., Rimsky, L., Vanveggel, S., Williams, P., & Boven, K. (2013). Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS (London, England), 27(6), 939-950. https://doi.org/10.1097/QAD.0b013e32835cee6e